Current status of gene therapy strategies to treat HIV/AIDS

Molecular Therapy

Volumn 11, Issue 6, 2005, Pages 823-842

  Strayer, David S ^a   Akkina, Ramesh ^b   Bunnell, Bruce A ^c   Dropulic, Boro ^d   Planelles, Vicente ^e   Pomerantz, Roger J ^a   Rossi, John J ^f   Zaia, John A ^f  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d Lentigen Corporation   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

AIDS; Cellular cofactors; Gene therapy; Transduction; Viral vectors

Indexed keywords

6 O BENZYLGUANINE; ALPHA 1 ANTITRYPSIN; ALPHA2 INTERFERON; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; APTAMER; CARMUSTINE; CD34 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; COMPLEMENTARY RNA; CYCLOPHOSPHAMIDE; DIPHTHERIA TOXIN; DNA VACCINE; ETOPOSIDE; GAG PROTEIN; GENE PRODUCT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; I KAPPA B; INOSINATE DEHYDROGENASE; INTERFERON; LENTIVIRUS VECTOR; LIGAND; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; METHYLTRANSFERASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RANTES; RETROVIRUS VECTOR; REV PROTEIN; RIBOZYME; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SMALL INTERFERING RNA; STROMAL CELL DERIVED FACTOR 1; TEMOZOLOMIDE; THYMIDINE KINASE; TOXIN; TRANSACTIVATOR PROTEIN; VIF PROTEIN; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELL POPULATION; CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; DISEASE MODEL; DNA MODIFICATION; EXPERIMENTAL DESIGN; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TECHNOLOGY; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IN VITRO STUDY; MURINE LEUKEMIA VIRUS; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOGENESIS; PROTEIN PROCESSING; PROVIRUS; REVIEW; RNA INTERFERENCE; SIDE EFFECT; SIMIAN VIRUS 40; T LYMPHOCYTE; TARGET CELL; TRANSGENE; TREATMENT PLANNING; UNCERTAINTY; VIRAL GENE DELIVERY SYSTEM; VIRUS ASSEMBLY; VIRUS DNA CELL DNA INTERACTION; VIRUS INHIBITION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; GENE THERAPY; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; MICE; MODELS, ANIMAL; TRANSGENES;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 19444370090     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.01.020     Document Type: Review

References (272)

1. S.J. Little et al.Reduced antiretroviral drug susceptibility among patients with primary HIV infection JAMA 282 1999 1142-1149
2. D. Pillay S. Taylor and D.D. Richman Incidence and impact of resistance against approved antiretroviral drugs Rev. Med. Virol. 10 2000 231-253
3. A.M. Wensig and C.A. Boucher Worldwide transmission of drug-resistant HIV AIDS Rev. 5 2003 140-155
4. C. Tamalet J. Fantini C. Tourres N. Yahi Resistance of HIV-1 to multiple antiretroviral drugs in France: A 6-year survey (1997-2002) based on analysis of over 7000 genotypes AIDS 17 2003 2383-2388
5. J.W. Tang and D. Pillay Transmission of HIV-1 drug resistance J. Clin. Virol. 30 2004 1-10
6. A. Lafeuillade H. Khiri S. Chadapaud G. Hittinger and P. Halfon Persistence of HIV-1 resistance in lymph node mononuclear cell RNA despite effective HAART AIDS 15 2001 1965-1999
7. J.M. Orenstein et al. Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression AIDS 14 2000 1709-1715
8. G.M. Ortiz et al. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects Proc. Natl. Acad. Sci. USA 98 2001 132288-132293
9. F. Martini et al. Acute human immunodeficiency virus replication causes a rapid and persistent impairment of Vγ9Vδ2 T cells in chronically infected patients undergoing structured treatment interruption J. Infect. Dis. 186 2002 847-850
10. M. Dybul et al. Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active retroviral therapy J. Virol. 77 2003 3229-3237
11. O. Lambotte et al. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution AIDS 18 2004 1147-1158
12. H. Goldstein M. Pettoello-Mantovani C.M. Anderson P. Cordelier R.J. and Pomerantz D.S. Strayer Gene therapy using a simian virus 40-derived vector inhibits the development of in vivo human immunodeficiency virus type 1 infection of severe combined immunodeficiency mice implanted with human fetal thymic and liver tissue J. Infect. Dis. 185 2002 1425-1430
13. D. Zhang et al. Optimization of ex vivo activation and expansion of macaque primary CD4-enriched peripheral blood mononuclear cells for use in anti-HIV immunotherapy and gene therapy strategies J. Acquired Immune Defic. Syndr. 32 2003 245-254
14. M. Patel P. Cordelier D.S. Strayer and H. Goldstein Potent in vivo inhibition of HIV-1 infection in Thy/Liv-SCID-Hu mice after in vivo treatment with a combination of SV40-derived vectors targeting CCR5 expression Mol. Ther. 9 2004 S141
15. D. Baltimore Gene therapy: Intracellular immunization Nature 335 1988 395-396
16. J.A. Zaia J.S. Cairns and J.J. Rossi AIDS and hematopoietic cell transplantation: HIV infection, AIDS lymphoma, and gene therapy In: K.G. Blume S.J. Forman F.R. Appelbaum (eds.), 3rd ed. Thomas' hematopoietic cell transplantation 2004 Blackwell Sci Boston
17. B.A. Bunnell and R.A. Morgan Gene therapy for infectious diseases Clin. Microbiol. Rev. 11 1998 42-56
18. R. Dornburg and R.J. Pomerantz HIV-1 gene therapy: Promise for the future Adv. Pharmacol. 49 2000 229-261
19. D. Trono M.B. Feinberg and D. Baltimore HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus Cell 59 1989 113-120
20. C. Woffendin U. Ranga Z. Yang L. Xu and G.J. Nabel Expression of a protective gene prolongs survival of T cells in human immunodeficiency virus-infected patients Proc. Natl. Acad. Sci. USA 93 1996 2889-2894
21. U. Ranga et al. Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals Proc. Natl. Acad. Sci. USA 95 1998 1201-1206
22. A. Caputo et al. Studies on the effect of the combined expression of anti-tat and anti-rev genes on HIV-1 replication Gene Ther. 4 1997 288-295
23. J. Chinen E. Aguilar-Cordova D. Ng-Tang D.E. Lewis and J.W. Belmont Protection of primary human T cells from HIV infection by Trev: A transdominant fusion gene Hum. Gene Ther. 8 1997 861-868
24. S.M. Smith R.B. Markham and K.T. Jeang Conditional reduction of human immunodeficiency virus type 1 replication by a gain-of-herpes simplex virus 1 thymidine kinase function Proc. Natl. Acad. Sci. USA 93 1996 7955-7960
25. T.J. Curiel D.R. Cook Y. Wang B.H. Hahn S.K. Ghosh and G.S. Harrison Long-term inhibition of clinical and laboratory human immunodeficiency virus strains in human T-cell lines containing an HIV-regulated diphtheria toxin A chain gene Hum. Gene Ther. 4 1993 741-747
26. M.J. Schnell J.E. Johnson L. Buonocore and J.K. Rose Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection Cell 90 1997 849-857
27. T. Mebatsion S. Finke F. Weiland and K.K. Conzelmann A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells Cell 90 1997 841-847
28. A.G. Yang X. Bai X.F. Huang C. Yao and S. Chen Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection Proc. Natl. Acad. Sci. USA 94 1997 11567-11572
29. J.D. Chen X. Bai A.G. Yang Y. Cong and S.Y. Chen Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy Nat. Med. 3 1997 1110-1116
30. A.G. Yang X. Zhang F. Torti and S.Y. Chen Anti-HIV type 1 activity of wild-type and functional defective RANTES intrakine in primary human lymphocytes Hum. Gene Ther. 9 1998 2005-2018
31. B.C. Engle et al. Intrakines - evidence for a trans-cellular mechanism of action Mol. Ther. 1 2000 165-170
32. E. Gonzalez et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility Sci. Express 307 2005 (doi:10.1126/science.1101160)
33. 4 expressed under control of the viral long terminal repeat Proc. Natl. Acad. Sci. USA 90 1993 2695-2699
34. W.A. Marasco W.A. Haseltine and S.Y. Chen Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody Proc. Natl. Acad. Sci. USA 90 1993 7889-7893
35. L. Duan O. Bagasra M.A. Laughlin J.W. Oakes and R.J. Pomerantz Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody Proc. Natl. Acad. Sci. USA 91 1994 5075-5079
36. R. Levin et al. Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic Fab intrabodies against the matrix protein, p17 Mol. Med. 3 1997 96-110
37. I.J. Rondon and W.A. Marasco Intracellular antibodies (intrabodies) for gene therapy of infectious diseases Annu. Rev. Microbiol. 51 1997 257-283
38. P. Levy-Mintz et al. Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase J. Virol. 70 1996 8821-8832
39. J. Goodchild S. Agrawal M.P. Civeira P.S. Sarin D. Sun and P.C. Zamecnik Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides Proc. Natl. Acad. Sci. USA 85 1988 5507-5511
40. D.D. Ho R.J. Pomerantz and J.C. Kaplan Pathogenesis of infection with human immunodeficiency virus N. Engl. J. Med. 317 1987 278-286
41. C.M. Browning L. Cagnon P.D. Good J. Rossi D.R. Engelke and D.M. Markovitz Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 tat activation-response RNA decoy J. Virol. 73 1999 5191-5195
42. J.H. Kim R.J. McLinden J.D. Mosca M.T. Vahey W.C. Greene and R.R. Redfield Inhibition of HIV replication by sense and antisense rev response elements in HIV-based retroviral vectors J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 12 1996 343-351
43. H.M. Buck et al. Phosphate-methylated DNA aimed at HIV-1 RNA loops and integrated DNA inhibits viral infectivity Science 248 1990 208-212
44. J. Lisziewicz D. Sun M. Klotman S. Agrawal P. Zamecnik and R. Gallo Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: An in vitro model for treatment Proc. Natl. Acad. Sci. USA 89 1992 11209-11213
45. H.K. Chang R. Gendelman J. Lisziewicz R.C. Gallo and B. Ensoli Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: A strategy for control of HIV-1 Gene Ther. 1 1994 208-216
46. B.A. Sullenger H.F. Gallardo G.E. Ungers and E. Gilboa Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication Cell 63 1990 601-608
47. R.A. Morgan and R. Walker Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins Hum. Gene Ther. 7 1996 1281-1306
48. N. Sarver et al. Ribozymes as potential anti-HIV-1 therapeutic agents Science 247 1990 1222-1225
49. J.J. Rossi et al. Ribozymes as therapies for AIDS Ann. N. Y. Acad. Sci. 616 1990 184-200
50. J.O. Ojwang A. Hampel D.J. Looney F. Wong-Staal and J. Rappaport Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme Proc. Natl. Acad. Sci. USA 89 1992 10802-10806
51. + hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo Mol. Ther. 1 2000 244-254
52. K. Konopka N.S. Lee J. Rossi and N. Duzgunes Rev-binding aptamer and CMV promoter act as decoys to inhibit HIV replication Gene 255 2000 235-244
53. L. Chaloin M.J. Lehmann G. Sczakiel and T. Restle Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1 Nucleic Acids Res. 30 2002 4001-4008
54. J. Bai J. Rossi and R. Akkina Multivalent anti-CCR5 ribozymes for stem cell based HIV type 1 gene therapy AIDS Res. Hum. Retroviruses 17 2001 385-399
55. Y. Feng et al. Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor-5 Virology 276 2000 271-278
56. N.S. Lee et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells Nat. Biotechnol. 20 2002 500-505
57. M.A. Martinez et al. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication AIDS 16 2002 2385-2390
58. X.-F. Qin D. Sung An I.S.Y. Chen and D. Baltimore Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5 Proc. Natl. Acad. Sci. USA 100 2003 183-188
59. R.J. Pomerantz RNA interference meets HIV-1: Will silence be golden? Nat. Med. 8 2002 659-660
60. J.M. Jacque K. Triques and M. Stevenson Modulation of HIV-1 replication by RNA interference Nature 418 2002 435-438
61. A.T. Das et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition J. Virol. 78 2004 2601-2605
62. D.S. Strayer F. Branco J. Landré M. BouHamdan F. Shaheen and R.J. Pomerantz Combination genetic therapy to inhibit HIV-1 Mol. Ther. 5 2002 33-41
63. D. Boden O. Pusch F. Lee L. Tucker and B. Ramratnam Human immunodeficiency virus type 1 escape from RNA interference J. Virol. 77 2003 11531-11535
64. M.J. Li et al. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs Mol. Ther. 8 2003 196-206
65. J. Anderson A. Banerjea V. Planelles and R. Akkina Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA AIDS Res. Hum. Retroviruses 19 2003 699-706
66. C. Butticaz et al. Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression Antiviral Ther. 8 2003 373-377
67. M.A. Martinez et al. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication AIDS 16 2002 2385-2390
68. C.D. Novina et al. siRNA-directed inhibition of HIV-1 infection Nat. Med. 8 2002 681-686
69. S.J. O'Brien and J.P. Moore The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS Immunol. Rev. 177 2000 99-111
70. J.L. Abad et al. Novel interfering bifunctional molecules against the CCR5 coreceptor are efficient inhibitors of HIV-1 infection Mol. Ther. 8 2003 475-484
71. R. Schroers C.M. Davis H.-J. Wagner and S.-Y. Chen Lentiviral transduction of human T-lymphocytes with a RANTES intrakine inhibits human immunodeficiency virus type 1 infection Gene Ther. 9 2002 889-897
72. P. Steinberger J. Andris-Widhopf B. Buhler B.R. Torbett and C.F. Barbas III Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion Proc. Natl. Acad. Sci. USA 97 2000 805-810
73. P. Cordelier B. Morse and D.S. Strayer Targeting CCR5 with siRNAs: Using recombinant SV40-derived vectors to protect macrophages and microglia from R5-tropic HIV Oligonucleotides 13 2003 281-294
74. J. Lama A. Mangasarian and D. Trono Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner Curr. Biol. 9 1999 622-631
75. J. Lama The physiological relevance of CD4 receptor down-modulation during HIV infection Curr. HIV Res. 1 2003 167-184
76. E.R. Argañaraz M. Schindler F. Kirchhoff and J. Lama Enhanced CD4 down-modulation by late-stage HIV-1 nef alleles is associated with increased Env incorporation and viral replication J. Biol. Chem. 36 2003 33912-33919
77. S. Carl et al. Modulation of different human immunodeficiency virus type 1 nef functions during progression to aids J. Virol. 75 2001 3657-3665
78. M. Tobiume M. Takahoko T. Yamada M. Tatsumi A. Iwamoto and M. Matsuda Inefficient enhancement of viral infectivity and CD4 downregulation by human immunodeficiency virus type 1 Nef from Japanese long-term nonprogressors J. Virol. 76 2002 5959-5965
79. H.M. Pham E.R. Arganaraz B. Groschel D. Trono and J. Lama Lentiviral vectors interfering with virus-induced CD4 down-modulation potently block human immunodeficiency virus type 1 replication in primary lymphocytes J. Virol. 78 2004 13072-13081
80. S.P. Goff Intracellular trafficking of retroviral genomes during the early phase of infection: Viral exploitation of cellular pathways J. Gene Med. 3 2001 517-528
81. M.I. Bukrinsky et al. Active nuclear import of human immuno-deficiency virus type 1 preintegration complexes Proc. Natl. Acad. Sci. USA 89 1992 6580-6584
82. A. Fassati D. Gorlich I. Harrison L. Zaytseva and J.M. Mingot Nuclear import of HIV-1 intracellular reverse transcription complexes is mediated by importin 7 EMBO J. 22 2003 3675-3685
83. P.D. Bieniasz Intrinsic immunity: A front-line defense against viral attack Nat Immunol. 5 2004 1109-1115
84. M. Stremlau C.M. Owens M.J. Perron M. Kiessling P. Autissier and J. Sodroski The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys Nature 427 2004 848-853
85. M.J. Perron M. Stremlau B. Song W. Ulm R.C. Mulligan and J. Sodroski TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells Proc. Natl. Acad. Sci. USA 101 2004 11827-11832
86. Z. Keckesova L.M. Ylinen and G.J. Towers The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities Proc. Natl. Acad. Sci. USA 101 2004 10780-10785
87. T. Hatziioannou D. Perez-Caballero A. Yang S. Cowan and P.D. Bieniasz Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha Proc. Natl. Acad. Sci. USA 101 2004 10774-10779
88. M. BouHamdan L.-X. Duan R.J. Pomerantz and D.S. Strayer Inhibition of HIV-1 by anti-integrase single-chain variable fragment (SFv): Delivery by SV40 provides durable protection against HIV-1 and does not require selection Gene Ther. 6 1999 660-666
89. K. Gao R.J. Gorelick D.G. Johnson and F. Bushman Cofactors for human immunodeficiency virus type 1 cDNA integration in vivo J. Virol. 77 2003 1598-1603
90. P. Cherepanov et al. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells J. Biol. Chem. 278 2003 372-381
91. M. Llano et al. LEDGF/p75 determines cellular trafficking of diverse lentiviral but not murine oncoretroviral integrase proteins and is a component of functional lentiviral preintegration complexes J. Virol. 78 2004 9524-9537
92. G. Maertens P. Cherepanov Z. Debyser Y. Engelborghs and A. Engelman Identification and characterization of a functional nuclear localization signal in the HIV-1 integrase interactor LEDGF/p75 J. Biol. Chem. 279 2004 33421-33429
93. M. Llano S. Delgado M. Vanegas and E.M. Poeschla LEDGF/p75 prevents proteasomal degradation of HIV-1 integrase J. Biol. Chem 279 2004 55570-55577
94. E. Yung M. Sorin E.J. Wang S. Perumal D. Ott and G.V. Kalpana Specificity of interaction of INI1/hSNF5 with retroviral integrases and its functional significance J. Virol. 78 2004 2222-2231
95. kB block Tat-tumor necrosis factor synergistic activation of human immunodeficiency virus type 1 gene expression and virus multiplication J. Virol. 70 1996 5777-5785
96. kB antagonists J. Virol. 71 1997 6485-6494
97. R.M. Surabhi and R.B. Gaynor RNA interference directed against viral and cellular targets inhibits human immunodeficiency virus type 1 replication J. Virol. 76 2002 12963-12973
98. J. Lisziewicz J. Rappaport and R. Dhar Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression New Biol. 3 1991 82-89
99. B.A. Sullenger H.F. Gallardo G.E. Ungers and E. Gilboa Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication Cell 63 1990 601-608
100. G.C. Jayan et al. SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional, and pol III promoters Gene Ther. 8 2001 1033-1042
101. J. Karn Tackling Tat J. Mol. Biol. 293 1999 235-254
102. K. Fujinaga D. Irwin M. Geyer and B.M. Peterlin Optimized chimeras between kinase-inactive mutant Cdk9 and truncated cyclin T1 proteins efficiently inhibit Tat transactivation and human immunodeficiency virus gene expression J. Virol. 76 2002 10873-10881
103. J. Kjems and P. Askjaer Rev protein and its cellular partners Adv. Pharmacol. 48 2000 251-299
104. S. Kubota and R.J. Pomerantz The nuclear function of the nuclear diffusion inhibitory signal of human immunodeficiency virus type 1 J. Hum. Virol. 3 2000 173-181
105. V.W. Pollard and M.H. Malim The HIV-1 Rev protein Annu. Rev. Microbiol. 52 1998 491-532
106. H. Zhang B. Yang R.J. Pomerantz C. Zhang S.C. Arunachalam and L. Gao The cytidine deamine CEM15 induces hypermutation in newly synthesized HIV-1 DNA Nature 424 2003 94-98
107. B. Mangeat P. Turell G. Caron M. Friedll L. Perrin and D. Trono Broad antiretroviral defense by human APOBEC3G through lethal editing of nascent reverse transcripts Nature 424 2003 99-103
108. K. Stopak C. de Noronha W. Yonemoto and W.C. Greene HIV-1 vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability Mol. Cell 12 2003 1-20
109. R. Mariani et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif Cell 114 2003 21-31
110. A.M. Sheehy N.C. Gaddis and M.H. Malim The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif Nat. Med. 9 2003 1404-1407
111. M. Mariana K.M. Rose S.L. Kozak and D. Kabat HIV-1 vif protein binds the editing enzyme APOBEC3G and induces its degradation Nat. Med. 9 2003 1398-1403
112. R.J. Pomerantz HIV-1 Vif: A tough viral nut to crack Nature 418 2002 594-595
113. W.C. Goh et al. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: A mechanism for selection of Vpr in vivo Nat. Med. 4 1998 65-71
114. Y. Zhu H.A. Gelbard M. Roshal S. Pursell B.D. Jamieson and V. Planelles Comparison of cell cycle arrest, transactivation, and apoptosis induced by the simian immunodeficiency virus SIVagm and human immunodeficiency virus type 1 vpr genes J. Virol. 75 2001 3791-3801
115. A. Brasey et al. The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle J. Virol. 77 2003 3939-3949
116. M. Roshal B. Kim Y. Zhu P. Nghiem and V. Planelles Activation of ATR-mediated DNA damage response by the HIV-1 viral protein R J. Biol. Chem. 278 2003 25879-25886
117. E.S. Zimmerman et al. Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation Mol. Cell. Biol. 24 2004 9286-9294
118. J.J. Lum et al. Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis J. Clin. Invest. 111 2003 1547-1554
119. J.L. Andersen, et al. (in press). ATR and GADD45alpha mediate HIV-1 VPR-induced apoptosis. Cell. Death Differ.
120. M. Moulard S. Hallenberger W. Garten and H.-D. Klenk Processing and routage of HIV glycoproteins by furin to the cell surface Virus Res. 60 1999 55-65
121. E. Decroly S. Bejannet D. Savaria and N.G. Seidah Comparative functional role of PC7 and furin in the processing of the HIV envelope glycoprotein gp160 FEBS Lett. 405 1997 68-72
122. N.M. Inocencio J.F. Sucic J.M. Moehring M.J. Spence and T.J. Moehring Endoprotease activities other than furin and PACE4 with a role in processing of HIV-1 gp160 glycoproteins in CHO-K1 cells J. Biol. Chem. 272 1997 1344-1348
123. L. Miranda J. Wolf S. Pichuantes R. Duke and A. Franzusoff Isolation of the human PC6 gene encoding the putative host protease for HIV-1 gp160 processing in T lymphocytes Proc. Natl. Acad. Sci. USA 93 1996 7695-7700
124. P. Cordelier M.A. Zern and D.S. Strayer HIV-1 proprotein processing as a target for gene therapy Gene Ther. 10 2003 467-477
125. P. Cordelier and D.S. Strayer Conditional expression of α1-antitrypsin delivered by recombinant SV40 vectors protects lymphocytes against HIV Gene Ther. 10 2003 2153-2156
126. P. Cordelier and D.S. Strayer Mechanisms of α1-antitrypsin inhibition of cellular serine proteases and HIV-1 protease that are essential for HIV-1 morphogenesis Biochim. Biophys. Acta 1638 2003 197-207
127. E.K. Franke H.E. Yuan and J. Luban Specific incorporation of cyclophilin A into HIV-1 virions Nature 372 1994 359-362
128. G.J. Towers T. Hatziioannou S. Cowan S.P. Goff J. Luban and P.D. Bieniasz Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors Nat. Med. 9 2003 1138-1143
129. O. Pornillos J.E. Garrus and W.I. Sundquist Mechanisms of enveloped RNA virus budding Trends Cell. Biol. 12 2002 569-579
130. J.E. Garrus et al. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding Cell 107 2001 55-65
131. U.K. von Schwedler et al. The protein network of HIV budding Cell 114 2003 701-713
132. M. Francis M. Meltzer and H. Gendelman Interferons in the persistence, pathogenesis, and treatment of HIV infection AIDS Res. Hum. Retroviruses 8 1992 199-207
133. P. Pitha Multiple effects of interferon on HIV-1 replication J. Interferon Res. 11 1991 313-318
134. C. Samuel Antiviral actions of interferon: Interferon-regulated cellular proteins and their surprisingly selective antiviral activities Virology 183 1991 1-11
135. D. Bednarik J. Mosca N. Raj and P. Pitha Inhibition of human immunodeficiency virus (HIV) replication by HIV-trans-activated alpha2-interferon Proc. Natl. Acad. Sci. USA 86 1989 4958-4962
136. A. Dolei A. Fattorossi R.D. Amelio F. Aiuti and F. Dianzani Direct and cell-mediated effects of interferon-alpha and -gamma on cells chronically infected with HTLV-III J. Interferon Res. 6 1986 543-549
137. H. Gendelman et al. Regulation of HIV replication in infected monocytes by interferon-alpha: Mechanisms for viral restriction J. Immunol. 145 1990 2669-2676
138. K. Hartshorn D. Neumeyer M. Vogt R. Schooley and M. Hirsch Activity of interferon alpha, beta and gamma against human immunodeficiency virus replication in vitro AIDS Res. Hum. Retroviruses 3 1987 125-133
139. R. Kornbluth P. Oh J. Munis P. Cleveland and D. Richman Interferons and bacterial lipopolysaccharide protects macrophages from productive infection by human immunodeficiency virus in vitro J. Exp. Med. 169 1989 1137-1151
140. G. Poli J. Orenstein A. Kinter T. Folks and A. Fauci Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines Science 244 1989 575-577
141. Y. Shirazi and P. Pitha Alpha interferon inhibits early stages of the human immunodeficiency virus type 1 replication cycle J. Virol. 66 1992 1321-1328
142. + T cells from virus-induced depletion in SCID mice transplanted with human cells Virology 253 1999 79-88
143. D. Ho et al. Recombinant human interferon alpha-A suppresses HTLV-III replication in vitro Lancet ii 1985 602-604
144. J. Yamamoto F. Barre-Sinoussi V. Bolton N. Pedersen and M. Gardner Human alpha- and beta-interferon but not gamma suppress the in vitro replication of LAV, HTLV-III, and ARV-2 J. Interferon Res. 6 1986 143-152
145. R. Pomerantz and M. Hirsch Interferon and human immunodeficiency virus infection Interferon 9 1987 113-127
146. P. Cordelier S. Calarota and D.S. Strayer Trans-activated IFNα2 delivered to T cells by SV40 inhibits early stages in the HIV-1 replicative cycle J. Hematother. Stem Cell Res. 11 2002 817-828
147. P. Cordelier S. Calarota R.J. Pomerantz X. Jiang and D.S. Strayer Inhibition of HIV-1 in the central nervous system by IFNα2 delivered by an SV40 vector J. Interferon Cytokine Res. 23 2003 477-488
148. S.A. Rosenberg et al. Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction N. Engl. J. Med. 323 1990 570-578
149. S.A. Rosenberg Karnofsky Memorial Lecture: The immunotherapy and gene therapy of cancer J. Clin. Oncol. 10 1992 180-199
150. L.J. Chang and J. He Retroviral vectors for gene therapy of AIDS and cancer Curr. Opin. Mol. Ther. 3 2001 468-475
151. T. Roe T.C. Reynolds G. Yu and P.O. Brown Integration of murine leukemia virus DNA depends on mitosis EMBO J. 12 1993 2099-2108
152. R.C. Hoeben A.A. Migchielsen R.C. van der Jagt H. van Ormondt A.J. and vander Eb Inactivation of the Moloney murine leukemia virus long terminal repeat in murine fibroblast cell lines is associated with methylation and dependent on its chromosomal position J. Virol. 65 1991 904-912
153. T.D. Palmer G.J. Rosman W.R. Osborne and A.D. Miller Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes Proc. Natl. Acad. Sci. USA 88 1991 1330-1334
154. D.A. Williams S.H. Orkin and R.C. Mulligan Retrovirus-mediated transfer of human adenosine deaminase gene sequences into cells in culture and into murine hematopoietic cells in vivo Proc. Natl. Acad. Sci. USA 83 1986 2566-2570
155. R.S. Mitchell et al. Retroviral DNA integration: ASLV, HIV and MLV show distinct target site preferences PloS Biol. 2 2004 1127-1136
156. L. Naldini et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector Science 272 1996 263-267
157. L. Naldini U. Blomer F.H. Gage D. Trono and I.M. Verma Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector Proc. Natl. Acad. Sci. USA 93 1996 11382-11388
158. Y.D. Korin and J.A. Zack Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells J. Virol. 72 1998 3161-3168
159. R.E. Sutton M.A. Reitsma N. Uchida and P.O. Bound Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1 based vectors is cell cycle dependent J. Virol. 73 1999 3649-3660
160. M. Manganini et al. A human immunodeficiency virus type 1 pol gene-derived sequence (cPPT/CTS) increases the efficiency of transduction of human nondividing monocytes and T lymphocytes by lentiviral vectors Hum. Gene Ther. 13 2002 1793-1807
161. A. Follenzi L.E. Ailles S. Bakovic N. Genua and L. Naldini Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences Nat. Genet. 25 2000 217-222
162. S. Cavalieri et al. Human T lymphocytes transduced by lentiviral vectors in the absence of TCR-activation maintain an intact immune competence Blood 102 2003 497-505
163. M.R. Mautino Lentiviral vectors for gene therapy of HIV-1 infection Curr. Gene Ther. 2 2002 23-43
164. B. Dropulic M. Hermanokova and P.M. Pitha A conditionally replicating HIV-1 vector interferes with wt-HIV-1 replication and spread Proc. Natl. Acad. Sci. USA 93 1996 11103-11108
165. M. Mukhtar H. Duke M. BouHamdan and R.J. Pomerantz Anti-human immunodeficiency virus type 1 gene therapy in human central nervous system-based cells: An initial approach against a potential virus reservoir Hum. Gene Ther. 11 2000 347-359
166. S. Pandya K. Boris-Lawrie N.J. Leung R. Akkina and V. Planelles Development of an Rev-independent, minimal simian immunodeficiency virus-derived vector system Hum. Gene Ther. 12 2001 847-857
167. E. Klimatcheva V. Planelles S.L. Day F. Fulreader M.J. Renda and J. Rosenblatt Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication Mol. Ther. 3 2001 928-939
168. M.R. Mautino and R.A. Morgan Enhanced inhibition of human immunodeficiency virus type 1 replication by novel lentiviral vectors expressing human immunodeficiency virus type 1 envelope antisense RNA Hum. Gene Ther. 13 2002 1027-1037
169. R. Schroers C.M. Davis H.-J. Wagner and S.-Y. Chen Lentiviral transduction of human T-lymphocytes with a RANTES intrakine inhibits human immunodeficiency virus type 1 infection Gene Ther. 9 2002 889-897
170. M.J. Li et al. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs Mol. Ther. 8 2002 196-206
171. P.N. Tsichlis Oncogenesis by Moloney murine leukemia virus Anticancer Res. 7 1987 171-180
172. P. Simmonds P. Balfe J.F. Peutherer C.A. Ludlam J.O. Bishop and A.J. Brown Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers J. Virol. 64 1990 864-872
173. Y. Li J.C. Kappes J.A. Conway R.W. Price G.M. Shaw and B.H. Hahn Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: Identification of replication-competent and -defective viral genomes J. Virol. 65 1991 3973-3985
174. A. Meyerhans et al. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations Cell 58 1989 901-910
175. + T cells Nat. Med. 9 2003 727-728
176. W. Hofman et al. Species-specific, postentry barriers to primate immunodeficiency virus infection J. Virol. 73 1999 10020-10028
177. R. Mariani et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif Cell 114 2003 21-31
178. L. Naldini et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector Science 272 1996 263-267
179. M. Marsh and A. Helenius Virus entry into animal cells Adv. Virus Res. 36 1989 107-151
180. M. Gasmi J. Glynn M.J. Jin D.J. Jolly K. Yee and S.T. Chen Requirements for efficient production and transduction of human immunodeficiency virus type 1-based vectors J. Virol. 73 1999 1828-1834
181. V.N. Kim K. Mitrophanous S.M. Kingsman and A.J. Kingsman Minimal
182. R. Zufferey D. Nagy R.J. Mandel L. Naldini and D. Trono Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo Nat. Biotechnol. 15 1997 871-875
183. D. Trono HIV accessory proteins: Leading roles for the supporting cast Cell 82 1995 189-192
184. T. Dull et al. A third-generation lentivirus vector with a conditional packaging system J. Virol. 72 1998 8463-8471
185. H. Miyoshi U. Blomer M. Takahashi F.H. Gage and I.M. Verma Development of a self-inactivating lentivirus vector J. Virol. 72 1998 8150-8157
186. R. Zufferey et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery J. Virol. 72 1998 9873-9880
187. A.C. Logan D.L. Haas T. Kafri and D.B. Kohn Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration J. Virol. 78 2004 8421-8436
188. E. Kotsopoulou V.N. Kim A.J. Kingsman S.M. Kingsman and K.A. Mitrophanous A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene J. Virol. 74 2000 4839-4852
189. M.J. Gething and J. Sambrook Cell-surface expression of influenza haemagglutinin from a cloned DNA copy of the RNA gene Nature 293 1981 620-625
190. D.S. Strayer M.A. Zern and J.R. Chowdhury What can SV40-derived vectors do for gene therapy? Curr. Opin. Mol. Ther. 4 2002 313-323
191. R. Kondo M.A. Feitelson and D.S. Strayer Use of SV40 to immunize against hepatitis B surface antigen: Implications for the use of SV40 for gene transduction and its use as an immunizing agent Gene Ther. 5 1998 575-582
192. H.J. McKee and D.S. Strayer Immune response against SIV envelope glycoprotein, using recombinant SV40 as a vaccine delivery vector Vaccine 20 2002 3613-3625
193. B.V. Sauter et al. Gene transfer to the liver using a replication-deficient recombinant SV40 vector results in long-term amelioration of jaundice in Gunn rats Gastroenterology 119 2000 1348-1357
194. D.S. Strayer et al. Efficient gene transfer to hematopoietic progenitor cells using SV40-derived vectors Gene Ther. 7 2000 886-895
195. D.S. Strayer R. Kondo J. Milano and L.-X. Duan Use of SV40-based vectors to transduce foreign genes to normal human peripheral blood mononuclear cells Gene Ther. 4 1997 219-225
196. M. BouHamdan et al. Inhibition of HIV-1 infection by down-regulation of the CXCR4 co-receptor using an intracellular single chain variable fragment against CXCR4 Gene Ther. 8 2001 408-418
197. P. Cordelier et al. Protecting from R5-tropic HIV: Individual and combined effectiveness of a hammerhead ribozyme and a single chain Fv antibody that target CCR5 Gene Ther. 11 2004 1627-1637
198. B. Liu J. Daviau and D.S. Strayer Direct in vivo gene delivery into hematopoietic stem cell using recombinant SV40 viral vector Blood 102 2003 498b [Abstract 5724]
199. J.M. McCune Animal models of HIV-1 disease Science 278 1997 2141-2142
200. D. Mosier Human xenograft models for virus infection Virology 271 2000 215-219
201. B.D. Jamieson and J.A. Zack Murine models for HIV disease AIDS 13 1999 S5-S11
202. T.R. Kollmann et al. Divergent effects of chronic HIV-1 infection on human thymocyte maturation in SCID-hu mice J. Immunol. 154 1995 907-921
203. R.K. Akkina J.D. Rosenblatt A.G. Campbell I.S.Y. Chen and J.A. Zack Modeling human lymphoid precursor cell gene therapy in the SCID-hu mouse Blood 84 1994 1393-1398
204. R. Akkina A. Banerjea J. Bai J. Anderson M.J. Li and J.J. Rossi siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS AntiCancer Res. 23 2003 1997-2005
205. M.L. Bonyhadi et al. RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication J. Virol. 71 1997 4707-4716
206. N.K. Banda et al. Diphtheria toxin A gene mediated HIV-1 protection of cord blood derived T cells in the SCID-hu mouse model J. Hematother. 7 1998 319-331
207. + hematopoietic progenitor cells in vitro and a SCID-hu mouse model in vivo Mol. Ther. 1 2000 244-254
208. J. Bai N. Banda N.S. Lee J.J. Rossi and R. Akkina RNA based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model Mol. Ther. 6 2002 770-782
209. + progenitor cell-derived macrophages Mol. Ther. 8 2003 62-71
210. G.A. Coburn and B.R. Cullen siRNAs: A new wave of RNA-based therapeutics J. Antimicrobial Chemother. 51 2003 753-756
211. L.J. Scherer and J.J. Rossi Approaches for the sequence-specific knockdown of mRNA Nat. Biotechnol. 21 2003 1457-1465
212. J. Anderson A. Banerjea and R. Akkina Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance Oligonucleotides 13 2003 303-312
213. Y. Hanazono K. Terao and K. Ozawa Gene transfer into nonhuman primate hematopoietic stem cells: Implications for gene therapy Stem Cells 19 2001 12-23
214. R.E. Donahue and C.E. Dunbar Update on the use of nonhuman primate models for preclinical testing of gene therapy approaches targeting hematopoietic cells Hum. Gene Ther. 12 2001 607-617
215. C.E. Dunbar The use of nonhuman primate models to improve gene transfer into hematopoietic stem cells J. Intern. Med. 249 2001 329-338
216. V.M. Hirsch and J.D. Lifson Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis Adv. Pharmacol. 49 2000 437-477
217. R.C. Derosiers The simian immunodeficiency viruses Annu. Rev. Immunol. 8 1990 557-578
218. J. Li C.I. Lord W. Haseltine N.L. Letvin and J. Sodroski Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins J. Acquired Immune Defic. Syndr. 5 1992 639-646
219. C.D. Pilcher D.A. Wohl and D.B. Hicks Diagnosing primary HIV infection Ann. Intern. Med. 136 2002 488-489
220. J.V. Giorgi et al. Multicenter AIDS Cohort Study: Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection J. Acquired Immune Defic. Syndr. 29 2002 346-355
221. G.B. Baskin M. Murphey-Corb E.A. Watson and L.N. Martin Necropsy findings in rhesus monkeys experimentally infected with cultured simian immunodeficiency virus (SIV)/delta Vet. Pathol. 25 1988 456-467
222. V.M. Hirsch and R.P. Johnson Pathogenic diversity of simian immunodeficiency viruses Virus Res. 32 1994 183-203
223. H.M. McClure D. Anderson P.N. Fultz A.A. Ansari E. Lockwood and A. Brodie Spectrum of disease in macaque monkeys chronically infected with SIVsmm Vet. Immunol. Immunopathol. 21 1989 13-24
224. P.J. Goulder et al. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection J. Exp. Med. 193 2001 181-194
225. B.R. Mothe et al. Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection J. Virol. 76 2002 875-884
226. G. Pantaleo et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia Proc. Natl. Acad. Sci. USA 94 1997 254-258
227. T.M. Allen et al. CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: Implications for vaccine design and testing J. Virol. 75 2001 738-749
228. M.J. Kuroda et al. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys J. Immunol. 162 1999 5127-5133
229. X. Jin et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques J. Exp. Med. 189 1999 991-998
230. T. Matano R. Shibata C. Siemon M. Connors H.C. Lane and M.A. Martin Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques J. Virol. 72 1998 164-169
231. + lymphocytes Science 283 1999 857-860
232. M.J. Kuroda et al. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex J. Exp. Med. 187 1998 1373-1381
233. J.D. Altman et al. Phenotypic analysis of antigen-specific T lymphocytes Science 274 1996 94-96
234. H.T. Maecker et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry J. Immunol. Methods 255 2001 27-40
235. D.C. Montefiori T.S. Hill H.T. Vo B.D. Walker and E.S. Rosenberg Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection J. Virol. 75 2001 10200-10207
236. + hematopoietic progenitor cells with an antitat gene protects T-cell and macrophage progeny from AIDS virus infection J. Virol. 71 1997 2740-2746
237. + hematopoietic progenitor cells with a hairpin ribozyme protects T cells and macrophages from simian immunodeficiency virus infection Blood 90 1997 4822-4831
238. S.R. Riddell et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients Nat. Med. 2 1996 216-223
239. S.J. Brodie et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells Nat. Med. 5 1999 34-41
240. R. Tan et al. Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome Blood 93 1999 1506-1510
241. R.E. Walker et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection Blood 96 2000 467-474
242. R.T. Mitsuyasu et al. Prolonged survival and tissue trafficking following adoptive transfer of CDζ gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects Blood 96 2000 785-793
243. + T cells in the absence of exogenous feeder cells J. Immunol. 159 1997 5921-5930
244. + T cell proliferation in HIV-positive patients as a result of CD28 costimulation Science 272 1996 1939-1943
245. + T cells Science 276 1997 273-276
246. R.G. Carroll J.L. Riley B.L. Levine P.J. Blair D.C. St Louis and C.H. June The role of co-stimulation in regulation of chemokine receptor expression and HIV-1 infection in primary T lymphocytes Semin. Immunol. 10 1998 195-202
247. + T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection Nat. Med. 8 2002 47-53
248. S. Chatterjee and K.K. Wong Jr. Adeno-associated virus vectors for gene therapy of the hematopoietic system Curr. Top. Microbiol. Immunol. 218 1996 61-73
249. + hematopoietic progenitor cells: Donor variation and correlation of transgene expression with cellular differentiation J. Virol. 71 1997 8262-8267
250. V.F. Van Tendeloo C. and Van Broeckhoven Z.N. Berneman Gene therapy: principles and applications to hematopoietic cells Leukemia 15 2001 523-544
251. D. Rund et al. Efficient transduction of human hematopoietic cells with the human multidrug resistance gene 1 via SV40 pseudovirions Hum. Gene Ther. 9 1998 649-657
252. D.B. Kohn and G.M. Crooks Clinical trials of gene marking and gene therapy using hematopoietic stem cells In K.G. Blume S.J. Forman F.R. Appelbaum (eds.), Blackwell Sci Boston Thomas' hematopoietic cell transplantation 2004 118-129
253. + cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes Blood 89 1997 2259-2267
254. A. Michienzi D. Castanotto N. Lee S. Li J.A. Zaia and J.J. Rossi RNA-mediated inhibition of HIV in a gene therapy setting Ann. N. Y. Acad. Sci. 1002 2003 63-71
255. D.B. Kohn et al. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children Blood 94 1999 368-371
256. A. Krishnan J. Zaia and A. Molina Stem cell transplantation and gene therapy for HIV-related lymphomas J. Hematother. Stem Cell Res. 11 2002 765-775
257. R.G. Amado et al. Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: Myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients Hum. Gene Ther. 15 2004 251-262
258. A. Nademanee et al. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma Clin. Lymphoma 1 2002 46-54
259. M. Cavazzana-Calvo et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease Science 288 2000 669-672
260. A. Aiuti et al. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement Nat. Med. 8 2002 423-425
261. 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea Cancer Res. 57 1997 5093-5099
262. 6-benzylguanine, and an alkyltransferase-expressing retroviral vector Mol. Ther. 3 2001 78-87
263. C.S. Brock et al. Phase I trial of temozolomide using an extended continuous oral schedule Cancer Res. 58 1998 4363-4367
264. L.C. Serrano and S. Gonzalez A novel drug selection system for isolating genetically modified human T lymphocytes utilizing a minimally manipulated human type II inosine monophosphate dehydrogenase Mol. Ther. 3 2001 152 Suppl.
265. T.S. Mele and P.F. Halloran The use of mycophenolate mofetil in transplant recipients Immunopharmacology 47 2000 215-245
266. J.J. Coull D. Turner T. Melby M.R. Betts R. Lanier and D.M. Margolis A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection J. Acquired Immune Defic. Syndr. 26 2001 423-434
267. D.M. Margolis et al. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA J. Acquired Immune Defic. Syndr. 31 2002 45-49
268. P. Yam Y. Ying J. Wu M. Jensen J. Zaia and J.-K. Yee Selective expansion of human T lymphocytes transduced by HIV vectors containing IMPDH2 and anti-HIV siRNA genes Am. Soc. Gene Ther. 7th Annual Meeting, Minneapolis, MN, USA 2004
269. R.R. MacGregor Clinical protocol: A phase 1 open-label clinical trial of the safety and tolerability of single escalating doses of autologous CD4 T cells transduced with VRX496 in HIV-positive subjects Hum. Gene Ther. 12 2001 2028-2029
270. A. Adachi et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone J. Virol. 59 1986 284-291
271. + infected patients grouped according to CD4 count and viral load Mol. Ther. 9 2004 902-913
272. X. Lu et al. Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance J. Virol. 78 2004 7079-7088